Bionano raises $10M upfront via registered direct offering; adds $20M potential from milestone warrants

Bionano Genomics, Inc.

17.5M shares/equivalents sold at $0.571/share for gross proceeds of ~$10M.
Concurrent private placement includes Series A & B warrants exercisable at $0.571/share, offering up to $20M additional.
Series A warrants expire 24 months post-stockholder approval or 60 days after MolDX coverage for optical genome mapping.
Series B warrants expire 5 years post-approval or 6 months after FDA clearance for optical genome mapping system.
Net proceeds earmarked for working capital, R&D, debt repayment, and capex; closing expected July 8, 2024.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.